Autologous Cell Therapy Market Size, Share & Trends Analysis Report By Application (Cancer, Neurodegenerative Disorders), Source (Bone Marrow, Mesenchymal Stem Cells), By End-use, By Region, And Segment Forecasts, 2024 - 2030
Autologous Cell Therapy Market Growth & Trends
The global autologous cell therapy market size is expected to reach USD 17.97 billion by 2030, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 22.20% from 2024 to 2030. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market. Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body.
During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.
In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience’ autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.
Autologous Cell Therapy Market Report Highlights
- The cancer segment dominated the market and accounted for a share of 29.9% in 2023. According to the American Cancer Society, it is anticipated that 1,958,310 new instances of cancer and 609,820 fatalities due to the disease.
- The bone marrow segment held the largest share of 29.9% in 2023. The bone marrow in autologous cell therapy has been successfully used to treat different diseases.
- The academics & research segment held the largest share of 39.05% in 2023 and is anticipated to grow rapidly from 2024 to 2030.
- North America autologous cell therapy market accounted for 36.68% share in 2023. The market is highly competitive since most of the major market players such as BrainStorm Cell Therapeutics and Bristol Myers Squibb operate in this region.
- Asia Pacific autologous cell therapy market is anticipated to witness fastest growth over the forecast period. owing to the rising burden of diseases, strong research activities in autologous cell therapies, the presence of a well-established biotechnology sector, developing healthcare facilities, and growing awareness for cell therapies.
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Application
- 1.2.2. Source
- 1.2.3. End Use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Application
- 2.2.2. Source outlook
- 2.2.3. End Use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Autologous Cell Therapy Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Numerous immunological advantages
- 3.2.1.2. Rise in the proportion of the geriatric population across the globe
- 3.2.1.3. Reduced risk of autologous cell therapy rejection
- 3.2.2. Market restraint analysis
- 3.2.2.1. High cost of treatment
- 3.2.2.2. Regulatory challenges
- 3.3. Autologous Cell Therapy Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.3. Pipeline Analysis
- Chapter 4. Autologous Cell Therapy Market: TApplication Estimates & Trend Analysis
- 4.1. Global Autologous Cell Therapy Market: Application Dashboard
- 4.2. Global Autologous Cell Therapy Market: Application Movement Analysis
- 4.3. Global Autologous Cell Therapy Market by Application, Revenue
- 4.4. Cancer
- 4.4.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Neurodegenerative disorders
- 4.5.1. Neurodegenerative disorders market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Cardiovascular disorders
- 4.6.1. Cardiovascular disorders market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Autoimmune disorders
- 4.7.1. Autoimmune disorders market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. Orthopedics
- 4.8.1. Orthopedics market estimates and forecasts 2018 to 2030 (USD Million)
- 4.9. Wound healing
- 4.9.1. Wound healing market estimates and forecasts 2018 to 2030 (USD Million)
- 4.10. Others
- 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 5. Autologous Cell Therapy Market: Source Estimates & Trend Analysis
- 5.1. Global Autologous Cell Therapy Market: Source Dashboard
- 5.2. Global Autologous Cell Therapy Market: Source Movement Analysis
- 5.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Source, Revenue (USD Million)
- 5.4. Bone Marrow
- 5.4.1. Bone marrow market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Epidermis
- 5.5.1. Epidermis market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Mesenchymal stem cells
- 5.6.1. Mesenchymal stem cells market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Haematopoietic stem cells
- 5.7.1. Haematopoietic stem cells market estimates and forecasts 2018 to 2030 (USD Million)
- 5.8. Chondrocytes
- 5.8.1. Chondrocytes market estimates and forecasts 2018 to 2030 (USD Million)
- 5.9. Others
- 5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 6. Autologous Cell Therapy Market: End Use Estimates & Trend Analysis
- 6.1. Global Autologous Cell Therapy Market: End Use Dashboard
- 6.2. Global Autologous Cell Therapy Market: End Use Movement Analysis
- 6.3. Global Autologous Cell Therapy Market Estimates and Forecasts, by End Use, Revenue (USD Million)
- 6.4. Hospitals & Clinics
- 6.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Ambulatory Centers
- 6.5.1. Ambulatory centers market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Academics & Research
- 6.6.1. Academics & research market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. Others
- 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 7. Autologous Cell Therapy Market: Regional Estimates & Trend Analysis by Application, Source, and End Use
- 7.1. Regional Dashboard
- 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.3. North America
- 7.3.1. U.S.
- 7.3.1.1. Key country dynamics
- 7.3.1.2. Regulatory framework/ reimbursement structure
- 7.3.1.3. Competitive scenario
- 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.2. Canada
- 7.3.2.1. Key country dynamics
- 7.3.2.2. Regulatory framework/ reimbursement structure
- 7.3.2.3. Competitive scenario
- 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.3. Mexico
- 7.3.3.1. Key country dynamics
- 7.3.3.2. Regulatory framework/ reimbursement structure
- 7.3.3.3. Competitive scenario
- 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework/ reimbursement structure
- 7.4.1.3. Competitive scenario
- 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Germany
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework/ reimbursement structure
- 7.4.2.3. Competitive scenario
- 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. France
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework/ reimbursement structure
- 7.4.3.3. Competitive scenario
- 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.4. Italy
- 7.4.4.1. Key country dynamics
- 7.4.4.2. Regulatory framework/ reimbursement structure
- 7.4.4.3. Competitive scenario
- 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.5. Spain
- 7.4.5.1. Key country dynamics
- 7.4.5.2. Regulatory framework/ reimbursement structure
- 7.4.5.3. Competitive scenario
- 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.6. Norway
- 7.4.6.1. Key country dynamics
- 7.4.6.2. Regulatory framework/ reimbursement structure
- 7.4.6.3. Competitive scenario
- 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.7. Sweden
- 7.4.7.1. Key country dynamics
- 7.4.7.2. Regulatory framework/ reimbursement structure
- 7.4.7.3. Competitive scenario
- 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.8. Denmark
- 7.4.8.1. Key country dynamics
- 7.4.8.2. Regulatory framework/ reimbursement structure
- 7.4.8.3. Competitive scenario
- 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/ reimbursement structure
- 7.5.1.3. Competitive scenario
- 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. China
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/ reimbursement structure
- 7.5.2.3. Competitive scenario
- 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. India
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework/ reimbursement structure
- 7.5.3.3. Competitive scenario
- 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Australia
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework/ reimbursement structure
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. South Korea
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework/ reimbursement structure
- 7.5.5.3. Competitive scenario
- 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Thailand
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework/ reimbursement structure
- 7.5.6.3. Competitive scenario
- 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework/ reimbursement structure
- 7.6.1.3. Competitive scenario
- 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. Argentina
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework/ reimbursement structure
- 7.6.2.3. Competitive scenario
- 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework/ reimbursement structure
- 7.7.1.3. Competitive scenario
- 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework/ reimbursement structure
- 7.7.2.3. Competitive scenario
- 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.3. UAE
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework/ reimbursement structure
- 7.7.3.3. Competitive scenario
- 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Regulatory framework/ reimbursement structure
- 7.7.4.3. Competitive scenario
- 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Company/Competition Categorization
- 8.2. Vendor Landscape
- 8.2.1. List of key distributors and channel partners
- 8.2.2. Key customers
- 8.2.3. Key company market share analysis, 2023
- 8.2.4. BrainStorm Cell Therapeutics
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Holostem Terapie Avanzate S.R.L
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. Pharmicell Co. Inc
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. Opexa Therapeutics
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. Caladrius Biosciences Inc
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. U.S. Stem Cell Inc
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.10. Lonza
- 8.2.10.1. Company overview
- 8.2.10.2. Financial performance
- 8.2.10.3. Product benchmarking
- 8.2.10.4. Strategic initiatives
- 8.2.11. Bristol Myers Squibb
- 8.2.11.1. Company overview
- 8.2.11.2. Financial performance
- 8.2.11.3. Product benchmarking
- 8.2.11.4. Strategic initiatives
- 8.2.12. Novartis AG.
- 8.2.12.1. Company overview
- 8.2.12.2. Financial performance
- 8.2.12.3. Product benchmarking
- 8.2.12.4. Strategic initiatives
- 8.2.13. Autolus therapeutics
- 8.2.13.1. Company overview
- 8.2.13.2. Financial performance
- 8.2.13.3. Product benchmarking
- 8.2.13.4. Strategic initiatives
- 8.2.14. Tego Science
- 8.2.14.1. Company overview
- 8.2.14.2. Financial performance
- 8.2.14.3. Product benchmarking
- 8.2.14.4. Strategic initiatives
- 8.2.15. Corning Incorporated
- 8.2.15.1. Company overview
- 8.2.15.2. Financial performance
- 8.2.15.3. Product benchmarking
- 8.2.15.4. Strategic initiatives
- 8.2.16. Bio Elpida
- 8.2.16.1. Company overview
- 8.2.16.2. Financial performance
- 8.2.16.3. Product benchmarking
- 8.2.16.4. Strategic initiatives
- 8.2.17. Vericel Corporation
- 8.2.17.1. Company overview
- 8.2.17.2. Financial performance
- 8.2.17.3. Product benchmarking
- 8.2.17.4. Strategic initiatives
- 8.2.18. Catalent, Inc
- 8.2.18.1. Company overview
- 8.2.18.2. Financial performance
- 8.2.18.3. Product benchmarking
- 8.2.18.4. Strategic initiatives
- 8.2.19. Sartorius AG
- 8.2.19.1. Company overview
- 8.2.19.2. Financial performance
- 8.2.19.3. Product benchmarking
- 8.2.19.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook